VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
INFU
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
INFUInfuSystem Holdings, Inc.
$13.69$276M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksINFUCash Flow

InfuSystem Holdings, Inc. (INFU) Cash Flow Statement

21Y historyFree accessUpdated daily

Cash conversion is unusually strong, with cumulative ten-quarter operating cash flow of ~$52.6M outstripping net income (~$13.2M) nearly fourfold and trailing four-quarter FCF of ~$19.1M, as capital intensity fell from 22.7% to 0.2% of revenue and buybacks accelerated to $4.2M in 2026Q2.

Income StatementBalance SheetCash FlowRatios

INFU Cash Flow Statement

Annual statement

INFU Cash Flow Statement

InfuSystem Holdings, Inc. (INFU) cash flow statement — 21-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05
Cash from Operations25.22M24.41M20.46M11.22M17.52M18.32M20.28M13.88M11.39M7.58M7.91M7.05M7.25M7.46M5.45M7.17M10.81M9.71M10.9M4.38M-912.35K0
Operating CF Margin %-17.02%15.17%8.92%15.94%17.89%20.82%17.11%16.97%10.67%11.22%9.78%10.91%11.98%9.27%13.13%22.89%24.92%30.77%66.5%--
Operating CF Growth %-37.17%19.3%82.3%-35.93%-4.36%-9.68%46.16%21.81%50.22%-4.12%12.12%-2.77%-2.79%36.89%-23.98%-33.67%11.37%-10.91%148.96%579.75%--
Net Income9.44M6.63M2.35M872K18K1.42M17.33M1.36M-1.09M-20.71M-222K3.74M3.36M1.67M-1.49M-45.44M-1.85M774K9.96M-2.8M-7.86M-24.78K
Depreciation & Amortization12.9M13.29M12.5M12.51M13.36M14.63M14.03M12.34M11.31M12.52M10.74M8.24M6.14M8.03M8.4M9.05M8.6M6.44M6.4M862K6.66M0
Stock-Based Compensation4.99M4.36M4.46M4.07M3.83M6.4M2.61M997K957K682K462K996K576K1.12M964K1.19M3.86M753K1.55M1.75M6.66T0
Deferred Taxes2.63M2.73M1.92M633K19K-153K-10.07M104K-62K15.39M-240K1.76M2.59M1.18M-906K-23.42M-1.24M2.25M935K335K-6.66T0
Other Non-Cash Items437K-2.51M-1.42M-1.3M-90K-1.29M-2.35M-741K5.23M5.07M5.07M5.11M4.5M5.08M4.42M76.07M4.18M4.43M-6.08M5.92M14.3M24.41K
Working Capital Changes-5.17M-94K652K-5.56M385K-2.69M-1.26M-188K-4.95M-5.38M-7.91M-12.8M-9.91M-9.62M-5.94M-10.27M-2.74M-4.94M-1.88M-1.7M-26.65K300
Change in Receivables-5.73M263K-701K-2.36M-1.15M829K-2.63M-1.56M-4.41M-5.45M-4.59M-9.14M-5.38M-8.72M-6.49M-4.87M-3.95M-1.83M-1.83M-698K00
Change in Inventory919K1.14M-126K-1.58M-882K-864K-102K-645K-490K402K-250K-158K-524K105K-30K-1.7M-506K-6.17M-2.98M6.27M00
Change in Payables-125K-708K-676K2.42M2.94M-2.36M2.39M2.44M183K-352K-3.15M-2.78M-4.03M-1.08M-335K-3.97M2.25M-601K-566K-1.75M102.89B0
Cash from Investing-9.95M-6.79M-13.24M-6.73M-11.48M-21.32M-12.16M-19.64M-4.98M1.05M-5.34M-11.91M-2.84M-2.16M-2.56M-5.55M-19.06M-4.61M-1.04M22.02M-96.96M0
Capital Expenditures-7.09M-8.69M-17.83M-11.12M-15.08M-16.66M-16.91M-22.59M-8.3M-3.6M-8.79M-10.24M-9.71M-5.96M-6.54M-5.55M-2.44M-4.61M-1.73M-553K00
CapEx % of Revenue4.91%6.06%13.22%8.84%13.72%16.27%17.37%27.86%12.37%5.06%12.48%14.2%14.6%9.57%11.12%10.16%5.17%11.84%4.89%8.4%--
Acquisitions-577K-1.41M003.6M-7.98M4.75M2.95M3.32M3.87M-370K-6.16M0000-16.62M784K784K-8.69M-741.66K0
Investments----------------------
Other Investing-3.96M3.31M4.59M4.38M3.6M3.32M003.32M4.65M3.82M4.49M6.87M3.8M3.98M-1.4M0-783K-95K31.26M-741.66B0
Cash from Financing-7.12M-14.96M-6.92M-4.42M-6.06M-6.46M-1.12M4.1M-5.56M-8.56M15K5.16M-5.04M-6.49M-1.37M-5.83M5.51M-8.86M-2.3M-22.86M98.28M13.67K
Debt Issued (Net)-1.36M-4.12M-5.32M-3.95M-13K-5.47M407K4.57M4.84M-8.6M-107K5.23M-4.84M-6.41M-1.22M-5.37M6.55M-8.72M-2.1M-409K-85K60K
Equity Issued (Net)-5.77M-10.64M-2M-1.31M-6.65M-1.73M-1.71M-717K-10.46M-58K-75K-179K-204K-79K-144K-465K-235K-135K0513K101.69M25K
Dividends Paid0000000000000000000000
Share Repurchases-7.11M-10.97M-2M-1.31M-6.65M-1.73M-1.71M-717K-10.46M-58K-75K-179K-204K-79K-144K-465K-235K-195K0000
Other Financing9K-197K387K835K605K738K190K246K64K93K197K108K0000-808K0-195K-22.97M-3.32M-71.33K
Net Change in Cash8.15M2.66M296K66K-21K-9.46M7M-1.67M849K71K2.58M303K-623K-1.19M1.53M-4.21M-2.74M-3.76M7.55M3.53M413.78K13.59K
Free Cash Flow19.81M15.72M2.63M106K2.44M1.66M3.37M-8.72M3.09M3.99M-886K-3.19M-2.45M1.5M-1.09M1.62M8.37M5.1M9.16M3.82M-912.35K0
FCF Margin %13.71%10.96%1.95%0.08%2.22%1.62%3.46%-10.75%4.6%5.61%-1.26%-4.42%-3.68%2.41%-1.85%2.96%17.72%13.08%25.88%58.1%--
FCF Growth %38.18%498.71%2377.36%-95.66%47.05%-50.68%138.6%-382.38%-22.57%550.11%72.23%-30.24%-263.22%237.71%-167.33%-80.65%64.21%-44.39%139.64%519.14%--
FCF per Share0.940.750.120.000.110.080.15-0.420.140.18-0.04-0.14-0.110.07-0.050.080.420.270.490.21-0.07-
FCF Conversion (FCF/Net Income)2.10x3.68x8.72x12.87x973.17x12.90x1.17x10.19x-10.40x-0.37x-35.63x1.88x2.16x4.47x-3.66x-0.16x-5.84x12.54x1.09x-1.57x0.12x-
Interest Paid01.24M1.75M2.05M1.31M1.11M1.21M1.71M1.38M1.2M1.23M1.51M2.35M2.67M3.11M1.93M2.37M2.93M3.12M000
Taxes Paid0543K753K213K153K171K102K111K159K139K105K146K298K549K79K249K21K18K533K000

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

Capex trailing depreciation run-rate

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Cash Conversion Exceeds Reported Earnings

Across the ten-quarter window, InfuSystem's cumulative operating cash flow of roughly $52.6M outstrips cumulative net income of about $13.2M by nearly four times, an exceptionally wide gap driven primarily by a $32.1M cumulative non-cash D&A charge, per company financial statements.

The divergence between GAAP earnings and operating cash flow is dominated by depreciation and amortization, which has run at $2.9M to $3.4M per quarter and frequently exceeds reported net income by itself. This pattern suggests a heavy depreciable asset base relative to reported profitability, meaning the low net margin likely understates underlying cash economics. However, quarters such as 2025Q1 and 2026Q1 show the OCF/NI ratio compressing sharply during loss-making periods, so the quality signal appears durable only on a cumulative rather than single-quarter basis.

FCF Inflects Sharply Positive

InfuSystem's free cash flow has swung from cumulative negative territory across 2024Q1-2024Q2 to $8.4M in 2026Q2 alone, with the trailing four-quarter FCF sum reaching approximately $19.1M, based on the company's cash flow disclosures.

The FCF trajectory points to a business that crossed an inflection in mid-2025, coinciding with the gross margin regime break identified in the income statement work. Volatility still matters: two of the ten quarters produced negative FCF (2024Q2 at -$5.3M and 2025Q1 at -$1.6M), each tied to capex spikes rather than operating deterioration. The 22.7% FCF margin in 2026Q2 compares favorably against peer OPRX's 18.6% and HCSG's 5.8%, but the sequential lumpiness argues against extrapolating the current run-rate linearly.

Capital Intensity Collapses Year-Over-Year

Capital expenditure as a percentage of revenue has fallen from 22.7% in 2024Q2 to just 0.2% in 2026Q2, a near-tenfold reduction that has freed meaningful cash for shareholder returns, as reported in InfuSystem's cash flow statements.

This collapse in capex intensity is one of the more consequential shifts in the model: quarterly capex peaked at $7.6M in 2024Q2 and has since settled below $1M in the most recent quarter, which may indicate completion of a growth investment cycle and a transition into harvest mode. The durability of such a low reinvestment rate warrants monitoring, because cumulative capex of roughly $28.3M over the window sits below the $32.1M cumulative D&A charge; a persistent gap between depreciation and capex typically implies asset base drawdown rather than efficiency.

Accrual Earnings Understate Cash Generation

The cumulative ten-quarter gap between operating cash flow (~$52.6M) and reported net income (~$13.2M) equals roughly $39.4M, indicating that non-cash charges rather than aggressive accruals explain the divergence, per InfuSystem's reported statements.

A gap of this magnitude in the direction of cash exceeding earnings is generally a favorable quality-of-earnings signal, suggesting reported net income is depressed by depreciation rather than inflated by aggressive revenue recognition, and cumulative D&A of approximately $32.1M accounts for the vast majority of the difference. Working capital, by contrast, has been a cumulative net drain of roughly $6.5M despite large quarterly swings, so the cash conversion advantage does not appear to rest on systematic payables stretching or inventory liquidation that would reverse.

Buybacks Accelerate as Capex Retreats

InfuSystem has deployed roughly $18.1M into share repurchases over the ten-quarter period, with quarterly buybacks rising from $365K in 2024Q1 to $4.2M in 2026Q2, an expansion that coincides with the sharp decline in capital expenditure.

The deployment pattern is consistent with a business entering a post-investment phase: no dividends have been paid, and the trailing four-quarter buyback total of approximately $9.3M represents a step-up versus the roughly $2.0M deployed across 2024Q1-2024Q3. A single $577K net acquisition in 2026Q2 suggests M&A remains opportunistic rather than a primary capital use. Because SBC continues to run near $1.2M per quarter, investors should cross-check the buyback pace against diluted share count trends in the filings to gauge the net reduction in shares actually outstanding.

What the Cash Flow Statement Obscures

Cumulative SBC of roughly $11.3M over the ten-quarter period is added back within operating cash flow, meaning the reported $52.6M of OCF embeds substantial non-cash compensation that may not be economically free, as disclosed in InfuSystem's filings.

The headline cash conversion strength should be discounted for two items the statement presentation can mask. First, SBC running near $1.2M per quarter, equal to roughly 38% of 2026Q2 net income, is a genuine economic cost that reduces OCF's comparability to cash available for shareholders; the accelerating buyback may partly be offsetting this dilution rather than retiring incremental capital. Second, capex has fallen to 0.2% of revenue against a $3.2M quarterly D&A charge, and if a meaningful share of the historical $28.3M capex represented maintenance rather than pure growth spend, current reinvestment may be insufficient to sustain the asset base. The recurring first-quarter working-capital drags (2025Q1 -$2.4M, 2026Q1 -$5.3M) also suggest an inherent seasonality that makes single-quarter FCF figures unreliable for annualizing.

INFU — Frequently Asked Questions

Quick answers to the most common questions about buying INFU stock.

How much cash does InfuSystem Holdings, Inc. (INFU) generate from operations?

InfuSystem Holdings, Inc. (INFU) generated $24.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is InfuSystem Holdings, Inc.'s free cash flow?

InfuSystem Holdings, Inc. (INFU) generated $15.7M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is InfuSystem Holdings, Inc.'s capital expenditure (CapEx)?

InfuSystem Holdings, Inc. (INFU) spent $8.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does InfuSystem Holdings, Inc. distribute cash to shareholders?

In 2025, InfuSystem Holdings, Inc. (INFU) spent $11.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.